Jishian Ravinthiran
@roosterjish.bsky.social
Gamer 👾. Previously Access to Medicines advocacy @Public Citizen. Views are my own.
New from @publiccitizen.bsky.social, @dndi.org, MSF-USA, KEI (@jamielove.bsky.social), Health GAP, and @mbarber.bsky.social
We urge NIH to ensure global access to publicly funded medicines by strengthening and implementing its draft policy on access planning when licensing NIH inventions
We urge NIH to ensure global access to publicly funded medicines by strengthening and implementing its draft policy on access planning when licensing NIH inventions
Integrating Equity Into Licensing Agreements For Taxpayer-Funded Technologies | Health Affairs Forefront
Current National Institutes of Health (NIH) policy allows corporations to commercialize medical technologies with few safeguards for global access. A new draft NIH policy begins to address that, but t...
www.healthaffairs.org
December 19, 2024 at 4:13 PM
New from @publiccitizen.bsky.social, @dndi.org, MSF-USA, KEI (@jamielove.bsky.social), Health GAP, and @mbarber.bsky.social
We urge NIH to ensure global access to publicly funded medicines by strengthening and implementing its draft policy on access planning when licensing NIH inventions
We urge NIH to ensure global access to publicly funded medicines by strengthening and implementing its draft policy on access planning when licensing NIH inventions
Reposted by Jishian Ravinthiran
Many Senate Judiciary Dems, who have voiced their concerns about drug prices, voted for PREVAIL. It is frustrating. The bill is clearly a Pharma handout that will give more power to branded drug companies to build patent thickets. Is this what the Dems stand for?
www.citizen.org/article/usin...
www.citizen.org/article/usin...
December 17, 2024 at 7:37 PM
Many Senate Judiciary Dems, who have voiced their concerns about drug prices, voted for PREVAIL. It is frustrating. The bill is clearly a Pharma handout that will give more power to branded drug companies to build patent thickets. Is this what the Dems stand for?
www.citizen.org/article/usin...
www.citizen.org/article/usin...
Reposted by Jishian Ravinthiran
This is why Pharma spends hundreds of millions of dollars lobbying the U.S Govt to erode the integrity of the patent system and prohibit Medicare from negotiating.
Report by @publiccitizen.bsky.social, @roosterjish.bsky.social: www.citizen.org/article/usin...
Report by @publiccitizen.bsky.social, @roosterjish.bsky.social: www.citizen.org/article/usin...
December 17, 2024 at 7:35 PM
This is why Pharma spends hundreds of millions of dollars lobbying the U.S Govt to erode the integrity of the patent system and prohibit Medicare from negotiating.
Report by @publiccitizen.bsky.social, @roosterjish.bsky.social: www.citizen.org/article/usin...
Report by @publiccitizen.bsky.social, @roosterjish.bsky.social: www.citizen.org/article/usin...
Reposted by Jishian Ravinthiran
Medicare’s lost savings for Enbrel, Stelara, Xarelto, and Januvia due to patent abuse: $4,912,545,821.61 to $5,390,261,854.07
Report by @publiccitizen.bsky.social, @roosterjish.bsky.social: www.citizen.org/article/usin...
Report by @publiccitizen.bsky.social, @roosterjish.bsky.social: www.citizen.org/article/usin...
December 17, 2024 at 7:34 PM
Medicare’s lost savings for Enbrel, Stelara, Xarelto, and Januvia due to patent abuse: $4,912,545,821.61 to $5,390,261,854.07
Report by @publiccitizen.bsky.social, @roosterjish.bsky.social: www.citizen.org/article/usin...
Report by @publiccitizen.bsky.social, @roosterjish.bsky.social: www.citizen.org/article/usin...
Reposted by Jishian Ravinthiran
NEW: @publiccitizen.bsky.social reveals the billions of 💰 drug companies have extracted from Medicare by abusing the patent system to hike drug prices.
Medicare must heavily weigh the costs of patent abuse when negotiating maximum fair prices.
Medicare must heavily weigh the costs of patent abuse when negotiating maximum fair prices.
New report: We find pervasive patent abuses on the drugs selected for Medicare price negotiation, which deprive enrollees of access to affordable alternatives. Medicare will lose $5 billion due to these abuses, almost as much as it will save in the first year of negotiation.
Using the Inflation Reduction Act to Rein in Patenting & Evergreening Abuses - Public Citizen
www.citizen.org
December 16, 2024 at 11:12 PM
NEW: @publiccitizen.bsky.social reveals the billions of 💰 drug companies have extracted from Medicare by abusing the patent system to hike drug prices.
Medicare must heavily weigh the costs of patent abuse when negotiating maximum fair prices.
Medicare must heavily weigh the costs of patent abuse when negotiating maximum fair prices.
New report: We find pervasive patent abuses on the drugs selected for Medicare price negotiation, which deprive enrollees of access to affordable alternatives. Medicare will lose $5 billion due to these abuses, almost as much as it will save in the first year of negotiation.
Using the Inflation Reduction Act to Rein in Patenting & Evergreening Abuses - Public Citizen
www.citizen.org
December 12, 2024 at 4:36 PM
New report: We find pervasive patent abuses on the drugs selected for Medicare price negotiation, which deprive enrollees of access to affordable alternatives. Medicare will lose $5 billion due to these abuses, almost as much as it will save in the first year of negotiation.
Reposted by Jishian Ravinthiran
PURPOSE-2 results are now published. It demonstrates high level effectiveness of twice a year Lenacapavir for HIV prevention in Men and gender diverse persons.
An important milestone for long acting injectables for PrEP. Now we need to address the issue of access.
www.nejm.org/doi/full/10....
An important milestone for long acting injectables for PrEP. Now we need to address the issue of access.
www.nejm.org/doi/full/10....
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM
Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention
of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis
(PrEP) in cisgende...
www.nejm.org
November 28, 2024 at 12:47 PM
PURPOSE-2 results are now published. It demonstrates high level effectiveness of twice a year Lenacapavir for HIV prevention in Men and gender diverse persons.
An important milestone for long acting injectables for PrEP. Now we need to address the issue of access.
www.nejm.org/doi/full/10....
An important milestone for long acting injectables for PrEP. Now we need to address the issue of access.
www.nejm.org/doi/full/10....
Reposted by Jishian Ravinthiran
As stakeholders await final federal guidance on the use of government march-in rights, @roosterjish.bsky.social, @akesselheim.bsky.social, & Steve Knievel (@publiccitizen.bsky.social) outline a set of 7 key factors agencies should consider when deciding to use march-in rights to lower drug prices.
How Agencies Should Decide Which Costly Drugs To Target With Government March-In Rights | Health Affairs Forefront
March-in rights are vital safeguards that allow the federal government to license competitors when the owner is not making a taxpayer-funded invention reasonably available or cannot meet public health...
www.healthaffairs.org
November 25, 2024 at 4:45 PM
As stakeholders await final federal guidance on the use of government march-in rights, @roosterjish.bsky.social, @akesselheim.bsky.social, & Steve Knievel (@publiccitizen.bsky.social) outline a set of 7 key factors agencies should consider when deciding to use march-in rights to lower drug prices.
Reposted by Jishian Ravinthiran
A new Commonwealth Fund survey finds that a higher share of Medicare Advantage (MA) beneficiaries have problems affording healthcare vs. those with Traditional Medicare, particularly those with lower incomes.
Very much undercuts the narrative that MA provides better financial protection!
Very much undercuts the narrative that MA provides better financial protection!
November 24, 2024 at 3:51 AM
A new Commonwealth Fund survey finds that a higher share of Medicare Advantage (MA) beneficiaries have problems affording healthcare vs. those with Traditional Medicare, particularly those with lower incomes.
Very much undercuts the narrative that MA provides better financial protection!
Very much undercuts the narrative that MA provides better financial protection!
We identify the factors agencies can use to license generic competitors when a drug corporation engages in pricing abuses of a taxpayer funded drug. Using march-in rights could increase affordable access to lifesaving cancer and heart disease treatments for thousands of patients across the country
New study from @roosterjish.bsky.social @portalresearch.bsky.social @publiccitizen.bsky.social: which drugs are candidates for considering government march-in rights if found that excessive prices are affecting patient access (e.g., Xtandi, Erleada, Vyndamax): www.healthaffairs.org/content/fore...
How Agencies Should Decide Which Costly Drugs To Target With Government March-In Rights | Health Affairs Forefront
March-in rights are vital safeguards that allow the federal government to license competitors when the owner is not making a taxpayer-funded invention reasonably available or cannot meet public health...
www.healthaffairs.org
November 21, 2024 at 2:58 PM
We identify the factors agencies can use to license generic competitors when a drug corporation engages in pricing abuses of a taxpayer funded drug. Using march-in rights could increase affordable access to lifesaving cancer and heart disease treatments for thousands of patients across the country
🚨 Senate Judiciary is set to mark up the PREVAIL Act on Thursday, Nov 21.
The bill would, among other issues, make it harder for generic manufacturers to invalidate patent thickets that keep brand drug prices high #a2m #drugpricing
The bill would, among other issues, make it harder for generic manufacturers to invalidate patent thickets that keep brand drug prices high #a2m #drugpricing
November 19, 2024 at 8:35 PM
🚨 Senate Judiciary is set to mark up the PREVAIL Act on Thursday, Nov 21.
The bill would, among other issues, make it harder for generic manufacturers to invalidate patent thickets that keep brand drug prices high #a2m #drugpricing
The bill would, among other issues, make it harder for generic manufacturers to invalidate patent thickets that keep brand drug prices high #a2m #drugpricing